First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
作者信息
Lemery Steven, Keegan Patricia, Pazdur Richard
机构信息
From the Office of Hematology and Oncology Products (S.L., P.K.) and the Oncology Center of Excellence (R.P.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
出版信息
N Engl J Med. 2017 Oct 12;377(15):1409-1412. doi: 10.1056/NEJMp1709968.
PMID:29020592
Abstract
摘要
Zotero 插件